CLINICAL TRIALS PROFILE FOR ETEPLIRSEN
✉ Email this page to a colleague
All Clinical Trials for eteplirsen
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00844597 ↗ | Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients | Completed | British Medical Research Council | Phase 1/Phase 2 | 2009-01-01 | The specific aim of this Phase I/II study is to assess the safety of intravenous administered Morpholino oligomer directed against exon 51 (AVI-4658 PMO). |
NCT00844597 ↗ | Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients | Completed | Sarepta Therapeutics | Phase 1/Phase 2 | 2009-01-01 | The specific aim of this Phase I/II study is to assess the safety of intravenous administered Morpholino oligomer directed against exon 51 (AVI-4658 PMO). |
NCT00844597 ↗ | Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients | Completed | Sarepta Therapeutics, Inc. | Phase 1/Phase 2 | 2009-01-01 | The specific aim of this Phase I/II study is to assess the safety of intravenous administered Morpholino oligomer directed against exon 51 (AVI-4658 PMO). |
NCT01396239 ↗ | Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients | Completed | Sarepta Therapeutics | Phase 2 | 2011-07-01 | This study is designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of AVI-4658 (eteplirsen) in both 50.0 mg/kg and 30.0 mg/kg doses administered over 24 weeks in subjects diagnosed with Duchenne muscular dystrophy (DMD). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for eteplirsen
Condition Name
Clinical Trial Locations for eteplirsen
Trials by Country
Clinical Trial Progress for eteplirsen
Clinical Trial Phase
Clinical Trial Sponsors for eteplirsen
Sponsor Name